• Events
  • Workshop: 2020 World Health Summit
Workshop - Event date: 25 Oct 2020

2020 World Health Summit

The 2020 World Health Summit will take place from October 25-27. The conference, held in Berlin, will also be held digitally in light of the COVID-19 pandemic. Jayasree K. Iyer will join digitally to speak at three workshops.

Jayasree K. Iyer will join three workshops digitally during the World Health Summit. Details of each workshop are below.

1. Pandemic Preparedness in the Age of COVID-19
Hosted by Charité - Universitätsmedizin Berlin; Foundation for Innovative New Diagnostics (FIND); London School of Hygiene & Tropical Medicine (LSHTM); M8 Alliance.

Digital participation: https://worldhealthsummit-org.zoom.us/j/93528368344

COVID-19 has called our global pandemic preparedness into question. But building on experience with other coronaviruses, including SARS and MERS, and learning lessons from combatting outbreak diseases including Ebola, progress is being made with unprecedented speed to develop the tests, treatments and vaccines needed to keep the world safe. New forms of collaboration and strengthened partnerships have emerged as central to the response. From science and research to policy and implementation, the world has shifted in terms of our ability to react. How can we build back better after COVID-19, and ensure preparedness for the future?


  • Thomas Cueni, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Director-General | Switzerland
  • Prof. Dr. Christian Drosten. Charité - Universitätsmedizin Berlin | Institute of Virology Campus Charité Mitte | Director of the Institute | Germany
  • Dr. Tom Frieden, Resolve to Save Lives | President and CEO | United States of America
  • Dr. Jayasree K. Iyer, Access to Medicine Foundation | Executive Director | The Netherlands
  • Prof. Dr. Peter Piot, London School of Hygiene and Tropical Medicine (LSHTM) | Director and Professor of Global Health | United Kingdom

2. Innovations to Improve Pandemic Preparedness
Hosted by Johnson & Johnson

Digital participation: https://youtu.be/xruVNdSPw9w

Diagnostics, vaccines and treatments are critical tools to monitor and halt an epidemic, in addition to adequate production capabilities and equitable access and delivery of these tools. When the viral sequence of COVID-19 became available, scientists from both the private sector and academia immediately began the search for vaccines and treatments, mobilizing resources and forming partnerships to spur innovation. Governments around the world have announced research funding to combat this novel pathogen. What can be learned from the scientific response to COVID-19? How can we strengthen cross-sector partnerships for innovation against emerging health security threats? How to distribute treatments and vaccines? What mechanisms should be in place to accelerate the development new tools and technologies to protect global health security?


  • Dr. Catharina Boehme, Foundation for Innovative New Diagnostics (FIND) | CEO | Switzerland
  • Dr. Jayasree K. Iyer, Access to Medicine Foundation | Executive Director | The Netherlands
  • Dr. Paul Stoffels, Johnson & Johnson | Vice Chair of the Executive Committee and Chief Scientific Officer | United States of America
  • Prof. Dr. Veronika von Messling, Federal Ministry of Education and Research (BMBF) | Life Sciences Division | Director-General | Germany
  • Sir Andrew Witty, WHO Vaccine Development Program | Co-Lead

3. Access to Essential Medicines in LMICs
Hosted by Medicines Patent Pool

Digital participation: https://worldhealthsummit-org.zoom.us/j/95587742850

Limited access to essential medicines is one of the key barriers to health. This is particularly true for the majority of low-and middle-income countries (LMICs). The barriers are varied and include weak health systems, no or lack of proper infrastructure, insufficient numbers of health workers, insufficient knowledge among health workers, no surveillance systems, lack of diagnostics. Price, of course, is a key barrier.

The price of patented medicines is becoming an increasing challenge in all countries, but in LMICs the proportion of healthcare spend on medicines is higher, at least a quarter and up to 67% of the entire healthcare budget, and this continues to increase. As a result, the price of medicines could make the implementation of Universal Health Coverage (UHC) unaffordable.

The answer to this challenge is to make medicines available and affordable, but the next question is how. A number of access models have been tried, including voluntary public health licensing, donation programs, tiered pricing, bilateral deals between originators and generic companies, and as a last resort compulsory or government licensing. The appropriateness of each model will depend on the specific circumstances but all should be judged against the major public health standards of transparency, sustainability, and benefit.


  • Prof. Dr. Graham Cooke, Imperial College | Wright-Fleming Institute | NIHR Research Professor of Infectious Diseases | United Kingdom
  • Dr. Jayasree K. Iyer, Access to Medicine Foundation | Executive Director | The Netherlands
  • Maurine Murenga, Lean on Me Foundation | Executive Director | Kenya
  • Dr. Mariângela Simão, World Health Organization (WHO) | Assistant Director General, Access to Medicines, Vaccines and Pharmaceuticals
  • Marisol Touraine, Unitaid | Chair of the Executive Board

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |